Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bloomage BioTechnologySHSE:688363 +0.56%94 ROC (Joel Greenblatt) % is 7.29% as of Jun. 2026, which is 82% below its 10-year median of 39.48. GuruFocus rates SHSE:688363 with a GF Score™ of 94/100 and a GF Value™ of ¥39.03 (Fairly Valued). The stock has 8 warning signs investors should review. Among 1,609 Chemicals companies, Bloomage BioTechnology ranks worse than 68.18% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Bloomage BioTechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 7.29%.
The historical rank and industry rank for Bloomage BioTechnology's ROC (Joel Greenblatt) % or its related term are showing as below:
SHSE:688363'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.82 Med: 39.48 Max: 67.48
Current: 4.85
During the past 10 years, Bloomage BioTechnology's highest ROC (Joel Greenblatt) % was 67.48%. The lowest was 4.82%. And the median was 39.48%.
SHSE:688363's ROC (Joel Greenblatt) % is ranked worse than 68.18% of 1609
companies
in the Chemicals industry
Industry Median: 10.56
vs SHSE:688363: 4.85
Bloomage BioTechnology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -35.70% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Bloomage BioTechnology ROC (Joel Greenblatt) % Related Terms
Bloomage BioTechnology ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Bloomage BioTechnology's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688363 vs LIN, SHW, ECL: ROC (Joel Greenblatt) % Comparison
For the Specialty Chemicals subindustry, Bloomage BioTechnology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bloomage BioTechnology ROC (Joel Greenblatt) % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Bloomage BioTechnology's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Bloomage BioTechnology's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 7.29% mean?
Bloomage BioTechnology (SHSE:688363) has a ROC (Joel Greenblatt) % of 7.29% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bloomage BioTechnology and its competitors. This is 82% below median its historical median of 39.48. Over the past decade, Bloomage BioTechnology's ROC (Joel Greenblatt) % has ranged from 4.82 to 67.48. According to the industry distribution chart, Bloomage BioTechnology ranks #1097 out of 1609 companies in the Chemicals industry, placing it in the top 68.2%.
Is Bloomage BioTechnology's ROC (Joel Greenblatt) % too high?
Bloomage BioTechnology's current ROC (Joel Greenblatt) % of 7.29% is 82% below median its 10-year median of 39.48. Over the past 10 years, this metric has ranged from a low of 4.82 to a high of 67.48. The Chemicals industry median ROC (Joel Greenblatt) % is 10.56. Bloomage BioTechnology's value of 7.29% is 31% below this industry median. Based on the distribution chart, Bloomage BioTechnology ranks #1097 out of 1609 companies in the Chemicals industry, which is below the industry midpoint. Overall, Bloomage BioTechnology has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bloomage BioTechnology's ROC (Joel Greenblatt) % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Bloomage BioTechnology ranks #1097 out of 1609 companies for ROC (Joel Greenblatt) %. This places Bloomage BioTechnology in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 10.56. Bloomage BioTechnology's value of 7.29% is 31% below this benchmark. Historically, Bloomage BioTechnology's own ROC (Joel Greenblatt) % has ranged from 4.82 to 67.48 over the past decade. While the company's 10-year median is 39.48 vs. the industry median of 10.56, Bloomage BioTechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Chemicals company?
The median ROC (Joel Greenblatt) % among Chemicals companies is 10.56, based on 1,609 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bloomage BioTechnology's current ROC (Joel Greenblatt) % of 7.29% is 31% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bloomage BioTechnology and its competitors. For the Chemicals industry, the median ROC (Joel Greenblatt) % is 10.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bloomage BioTechnology's current ROC (Joel Greenblatt) % is 7.29%, which is 82% below median its own 10-year median of 39.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bloomage BioTechnology stock overvalued right now?
Based on GuruFocus' analysis, Bloomage BioTechnology (SHSE:688363) is currently considered Fairly Valued. The stock's GF Value™ is ¥39.03, compared to a current price of ¥36.15 — trading 7.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 7.29%, which is 82% below median its 10-year median of 39.48 and 31% below the Chemicals industry median of 10.56. Bloomage BioTechnology's overall GF Score™ is 94/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Bloomage BioTechnology (SHSE:688363), the current ROC (Joel Greenblatt) % is 7.29% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bloomage BioTechnology (SHSE:688363) Overvalued in 2026?
Based on GuruFocus' analysis, Bloomage BioTechnology stock appears to be undervalued.
The current stock price of ¥36.15 is trading 7.4% below its estimated GF Value™ of ¥39.03.
GuruFocus considers Bloomage BioTechnology to be Fairly Valued.
Key valuation signals for SHSE:688363:
ROC (Joel Greenblatt) %: 7.29% (82% below median its 10-year median of 39.48)
GF Value™: ¥39.03 vs. price of ¥36.15 (7.4% below fair value)
Industry Position: 31% below the Chemicals median (#1097 of 1609)
No single metric tells the full story. See the SHSE:688363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bloomage BioTechnology Corp Ltd manufactures and sells a variety of chemicals and chemical-based products, typically made from hyaluronic acid or sodium hyaluronic acid. The company's products include raw materials, medical products, functional skincare, and functional foods. Raw materials, mainly hyaluronic acid, are used in pharmaceuticals, medical devices, cosmetics, and food. Medical products span beauty and therapeutic uses, such as viscoelastics, lubricants, fillers, and skin protectors. Skincare items include lotions, creams, and masks, while functional foods feature hyaluronic acid drinks and supplements.
94GF Score
Get the complete analysis for SHSE:688363
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688363 has been successfully added to your 
